VEGF News and Research RSS Feed - VEGF News and Research

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.
TSRI scientists reveal how vision-loss treatment may leave the eyes, kidneys vulnerable to cellular damage

TSRI scientists reveal how vision-loss treatment may leave the eyes, kidneys vulnerable to cellular damage

A common class of drugs for vision loss may actually add to the problem in some patients, according to new research co-led by scientists at The Scripps Research Institute (TSRI). [More]
Combination treatment may be valuable therapeutic option for HER2-negative metastatic breast cancer

Combination treatment may be valuable therapeutic option for HER2-negative metastatic breast cancer

Finding the ideal combination of targeted, hormonal and chemotherapeutic agents to treat HER2-negative metastatic breast cancer has been challenging researchers for decades. [More]
IQWiG finds colorectal cancer drug combination has added benefit only for some patients

IQWiG finds colorectal cancer drug combination has added benefit only for some patients

The fixed combination of trifluridine/tipiracil has been approved since April 2016 for the treatment of metastatic colorectal cancer. [More]
New review highlights challenges of studying resistance to antiangiogenic treatment in preclinical models

New review highlights challenges of studying resistance to antiangiogenic treatment in preclinical models

New blood vessel growth, or angiogenesis, is critical for cancer to grow and spread throughout the body. [More]
Researchers identify pathway that helps cancer cells to aggressively spread in the brain

Researchers identify pathway that helps cancer cells to aggressively spread in the brain

Glioblastoma multiforme remains the most common and highly lethal brain cancer and is known for its ability to relapse. [More]
Allergan, Amgen submit BLA for ABP 215 oncology biosimilar medicine to FDA

Allergan, Amgen submit BLA for ABP 215 oncology biosimilar medicine to FDA

Amgen and Allergan plc. today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 215, a biosimilar candidate to Avastin (bevacizumab). [More]
Experimental drug outperforms standard first-line therapy for advanced kidney cancer patients

Experimental drug outperforms standard first-line therapy for advanced kidney cancer patients

An experimental kidney cancer drug outperformed the standard first-line therapy for patients with metastatic disease who are considered at risk for poorer than average outcomes, according to results of a randomized phase II clinical trial by researchers at Dana-Farber Cancer Institute. [More]
High-altitude dwellers prone to chronic mountain sickness produce huge amounts of red blood cells

High-altitude dwellers prone to chronic mountain sickness produce huge amounts of red blood cells

To better understand why some people adapt well to life at high altitude while others don't, researchers at University of California San Diego School of Medicine studied red blood cells derived from representatives of both groups living in the Andes Mountains. [More]
Heart problems from common cancer treatment can be alleviated by using gene therapy

Heart problems from common cancer treatment can be alleviated by using gene therapy

Researchers of the Wihuri Research Institute and the University of Helsinki, Finland, have found that some of the harmful effects of a commonly used cancer drug can be alleviated by using gene therapy that stimulates blood vessel growth in the heart. [More]
ATS releases new clinical practice guidelines for diagnosis, management of LAM

ATS releases new clinical practice guidelines for diagnosis, management of LAM

The American Thoracic Society and the Japanese Respiratory Society have published new clinical practice guidelines for the diagnosis and management of lymphangioleiomyomatosis (LAM), a rare lung disease that primarily affects women of child-bearing age. [More]
HIF-2 inhibitors could be promising target to combat kidney cancer

HIF-2 inhibitors could be promising target to combat kidney cancer

A new class of drugs called HIF-2 inhibitors is more effective and better tolerated than the standard of care drug sunitinib in treating kidney cancer, researchers with the Kidney Cancer Program at Harold C. Simmons Comprehensive Cancer Center have found. [More]
Study suggests autologous EPC transfusion may prevent miscarriage in high-risk pregnancies

Study suggests autologous EPC transfusion may prevent miscarriage in high-risk pregnancies

In a study focusing on the role of self-donated (autologous) bone marrow-derived endothelial progenitor cells (EPCs) in placental vascular development, researchers in Japan have discovered that when transplanted into pregnant mice, EPCs can contribute to better blood vessel growth that helps in forming "normalized" placental vascularization, leading, in turn, to reduced recurrent miscarriages by providing a healthier fetal environment during gestation. [More]
People with high levels of four biomarkers may have increased risk for stroke

People with high levels of four biomarkers may have increased risk for stroke

People with high levels of four biomarkers in the blood may be more likely to develop a stroke than people with low levels of the biomarkers, according to a study published in the August 24, 2016, online issue of Neurology, the medical journal of the American Academy of Neurology. [More]
Scientists discover underlying mechanisms of proptosis in patients with thyroid eye disease

Scientists discover underlying mechanisms of proptosis in patients with thyroid eye disease

Researchers from the Schepens Eye Research Institute of Massachusetts Eye and Ear have identified new underlying mechanisms of proptosis, or bulging of the eyes, in patients with acute thyroid eye disease. [More]
Scientists discover key molecule that drives regeneration in planarian stem cells

Scientists discover key molecule that drives regeneration in planarian stem cells

Many living creatures possess exceptional abilities that set them apart from other species. Cheetahs can run up to 60 miles per hour; ants can lift 100 times their body weight; flatworms can regrow amputated body parts. [More]
Analysis of biopsies during early treatment predicts patient’s response to melanoma immunotherapy

Analysis of biopsies during early treatment predicts patient’s response to melanoma immunotherapy

Immune response measured in tumor biopsies during the course of early treatment predicts which melanoma patients will benefit from specific immune checkpoint blockade drugs, researchers at The University of Texas MD Anderson Cancer Center report in the journal Cancer Discovery. [More]
Researchers find potential way for delivering gene therapy to treat eye diseases

Researchers find potential way for delivering gene therapy to treat eye diseases

Eye diseases such as diabetic retinopathy and age-related macular degeneration are among the leading causes of irreversible vision loss and blindness worldwide. Currently, gene therapy can be administered to treat these conditions -- but this requires an injection. [More]
IU researchers create virtual tissue model of diabetic retinopathy

IU researchers create virtual tissue model of diabetic retinopathy

By combining data on optometry patient's eyes with advanced computational methods, Indiana University researchers have created a virtual tissue model of diabetes in the eye. [More]
Losing weight can lower levels of some proteins linked to tumor growth

Losing weight can lower levels of some proteins linked to tumor growth

Overweight and obese women who lost weight through diet and exercise lowered the levels of certain proteins in their blood that play a role in angiogenesis, the process of blood vessel growth that can promote the growth and survival of cancer cells [More]
Phase III clinical study of promising prostate cancer drug reveals surprising results

Phase III clinical study of promising prostate cancer drug reveals surprising results

A recently published international clinical Phase III trial of a promising drug for treating advanced prostate cancer ended with surprising results: the new therapeutic agent failed to achieve any significant improvement in the overall survival of patients compared with the established standard treatment. [More]
Advertisement
Advertisement